Angiotensin‐converting enzyme 2 (ACE2) receptor blocking antibodies, measured by the surrogate virus neutralizing test (sVNT) were found in 81.25% of individuals following both doses of the vaccine, while antibodies to the receptor‐binding domain (RBD) was significantly less than those following natural infection.4 This evidence concerns the gene ACE2 and infection.